FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/04/051813 [Registered on: 20/04/2023] Trial Registered Prospectively
Last Modified On: 19/04/2023
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group, Multiple Arm Trial 
Public Title of Study   A study was undertaken to see the spinal anaesthesia consequences in patients undergoing surgeries below navel region while using the local anaesthetics like levobupivacaine, bupivacaine and ropivacaine along with an additive nalbuphine 
Scientific Title of Study   A prospective randomized study comparing the effects of intrathecal hyperbaric levobupivacaine, bupivacaine and ropivacaine using nalbuphine as an adjuvant in elective infraumbilical surgeries 
Trial Acronym  Not applicable 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Nisha 
Designation  Junior resident 
Affiliation  PSG Institute of Medical Sciences and Research 
Address  Department of Anaesthesiology, PSG Institute of medical sciences and research, peelamedu, coimbatore
PSG Institute og medical sciences, Peelamedu, Coimbatore
Coimbatore
TAMIL NADU
641004
India 
Phone  9578788123  
Fax  -  
Email  dr.nisharavichandran04@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  R Arun Kumar 
Designation  Associate professor 
Affiliation  PSG IMSR 
Address  Department of Anaesthesiology, PSG Institute of Medical Sciences and Research, Peelamedi, Coimbatore
-
Coimbatore
TAMIL NADU
641004
India 
Phone  9944113440  
Fax  -  
Email  shivaaniarun76@gmail.com  
 
Details of Contact Person
Public Query
 
Name  G Nimi 
Designation  Assistant Professor 
Affiliation  PSG IMSR 
Address  Department of Anaesthesiology, PSG Institute of Medical Sciences and Research, Peelamedu, Coimbatore
-
Coimbatore
TAMIL NADU
641004
India 
Phone  8220812320  
Fax  -  
Email  nimi_5@yahoo.co.in  
 
Source of Monetary or Material Support  
PSG institute of medical sciences and research, PSG Hospitals, Coimbatore 
 
Primary Sponsor  
Name  PSG Institute of medical sciences and Research 
Address  PSG IMSR, Coimbatore 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
Nil  Not applicable 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
R Arun Kumar  PSG Hospitals  Department of Anaesthesiology, PSG Hospitals, Operation theatre complex, PSG Instittue of Medical Sciences and Research, Coimbatore
Coimbatore
TAMIL NADU 
9944113440
-
shivaaniarun76@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Human Ethics Committee, PSG Institute of Medical Sciences & Research  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: O||Medical and Surgical,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Levobupivacaine, Bupivacaine and Ropivacaine using Nalbuphine as an adjuvant  Dose : 0.5% Bupivacaine heavy 3.2ml with 0.6mg Nalbuphine (0.3ml) in group BN, 0.5% Levobupivacaine heavy 3.2ml with 0.6mg Nalbuphine (0.3ml) in group LN and 0.75% Ropivacaine with 0.6 mg Nalbuphine (0.3ml)in group RN. Route of administration - spinal anaesthesia Single dose administration Monitoring till 300 minutes post spinal anaesthesia for its clinical effects 
Intervention  Levobupivacaine, Bupivacaine and Ropivacaine with Nalbuphine  Group BN received 0.5% bupivacaine heavy 3.2ml with 0.6mg nalbuphine (0.3ml), Group LN received 0.5% levobupivaaine heavy 3.2ml with 0.6mg nalbuphine (0.3ml) and Group RN 0.75% Ropivacaine with 0.6 mg nalbuphine (0.3ml). Route of administration - spinal anaesthesia Single dose administration Monitoring till 300 minutes post spinal anaesthesia for its clinical effects 
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  50.00 Year(s)
Gender  Both 
Details  Patients acceptance,
Patients aged between 20 and 50 years,
ASA status 1 and 2 patients and
Patients undergoing elective infra umbilical surgeries under spinal anesthesia.
 
 
ExclusionCriteria 
Details  Absolute contraindication for spinal anesthesia,
Combined spinal-epidural anesthesia,
Known hypersensitivity or allergy to the study drugs,
Pregnancy and lactating mothers
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
The primary objective of this study is to compare the duration of motor blockade of hyperbaric levobupivacaine, bupivacaine and ropivacaine with nalbuphine adjuvant.   1, 3, 5, 10, 15, 30, 60, 90, 120, 180, 240 and 300 minutes 
 
Secondary Outcome  
Outcome  TimePoints 
The secondary objective focusses on the 1.Duration of sensory blockade 2.Effect of drugs on intraoperative haemodynamics 3.Time of regression of spinal anaesthesia 4.Side effects and complications of the hyperbaric levobupivacaine, bupivacaine and ropivacaine with nalbuphine as an adjuvant.  1, 3, 5, 10, 15, 30, 60, 90, 120, 180, 240 and 300 minutes  
 
Target Sample Size   Total Sample Size="120"
Sample Size from India="120" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   01/05/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   None yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

 120 patients will be divided into three groups of 40 each and randomly allocated to one of the three below-mentioned groups as Group BN - Bupivacaine with nalbuphine (n=40), Group LN - Levobupivacaine with nalbuphine (n=40) and Ropivacaine with nalbuphine (n=40) by computer generated program assigning random table number. Our study was a prospective randomized double-blinded study, where the patient and the primary investigator assessing the outcome were unaware of the group they were allotted.

     The method of randomization used was block randomization in which the study population was divided into sizes of six. The randomization codes for each subject were then enclosed in a sealed envelope, concealment ensured using sequentially numbered opaques sealed envelope, and the corresponding number was represented with the concerned group for the study. Prior to the study, the anaesthesiologist who were not involved in the study was made to pick among the lot of opaques concealed envelope which was handed over to the anaesthesiologist involved in the concerned surgery, who would admister the study drugs and observe the parameters.

     Group BN received 0.5% Heavy Bupivacaine (3.2ml) + 0.6mg of Nalbuphine   

                (0.3ml) to a total volume of 3.5 ml for spinal anesthesia

     Group LN received 0.5% Heavy Levobupivacaine (3.2ml) + 0.6mg of Nalbuphine

                (0.3ml) to a total volume of 3.5 ml for spinal anesthesia

     Group RN received 0.75% Heavy Ropivacaine (3.2ml) + 0.6mg of Nalbuphine

                 (0.3ml) to a total volume of 3.5 ml for spinal anesthesia

     Pre-anaesthetic evaluation was done on the day before surgery which includes detailed history, airway and systemic examination. Biochemical and pathological blood investigations were done. Starvation guidelines followed was 12 hours for fatty foods, 8 hours for solids and clear liquids encouraged till two hours prior to surgery. Antiaspiration prophylaxis was supplemented with Tablet.Pantoprazole 40mg and Tablet.Metoclopramide 10 mg the day before surgery at night 10 pm and informed written consent was obtained.

     On the day of surgery, before shifting the patient inside the operating room, starvation status, consent for surgery and anaesthesia including surgical safety checklist was done. An 18G intravenous cannula was secured intraoperatively and Plasmalyte intravenous fluids was started at a rate of 2ml/kg/hour. Basic monitoring gadgets like chest leads, noninvasive blood pressure monitoring, pulseoxymetry was attached after the patient was received in the operating table and baseline readings recorded. 

     The spinal anesthesia procedure was explained to the patient in their vernacular language. Under strict aseptic precautions, skin infiltration was done with 2ml of 2% lignocaine and a subarachnoid block performed with the patient in the left lateral position choosing preferably L3-L4 lumbar interspinous space using 25G Quincke spinal needle. After establishing free flow of CSF, the study drugs were supplemented to one among the three groups by random allocation number.

     The study medication was prepared by the person (another anaesthesiologist who was not involved in the study) to ensure the blinding of the anaesthesiologist. Group BN received 0.5% Heavy Bupivacaine (3.2ml) +0.6mg of Nalbuphine (0.3ml) to a total volume of 3.5ml, Group LN received 0.5% Heavy Levobupivacaine (3.2ml) +0.6mg of Nalbuphine (0.3ml) to a total volume of 3.5ml and Group RN received 0.75% Heavy Ropivacaine (3.2ml) +0.6mg of Nalbuphine (0.3ml) to a total volume of 3.5ml for spinal anesthesia and drug was administered over a duration of 35 seconds. Patient was turned supine post spinal injections and no table tilt was given to any of the groups.

     The following parameters were noted after obtaining subarachnoid blockade.

1.      Time of drug administration in spinal space

2.      Time of onset of complete sensory and motor block

3.      Duration of sensory block (sensory level was assessed by pin prick method)

4.      Duration of motor block (which was assessed by modified Bromage scale)

5.      Duration of postoperative analgesia (Effective analgesia time of onset of sensory block to the first request of rescue analgesics by using VAS score)

6.      Time for complete regression of spinal anesthesia

7.      Modified Bromage Scale

8.      Text Box: Modified Bromage scale  Grade                      Description     1		Complete block (unable to move feet or knees)     2		Almost complete block (able to move feet only)     3		Partial block (just able to move knees)     4		Detectable weakness of hip flexion (between scores 3 and 5)     5		No detectable weakness of hip flexion while supine (Full flexion of 			knees)     6		Able to perform partial knee bend  Haemodynamic parameters like heart rate, blood pressure, and oxygen saturation

Results for the study were recorded from baseline and continued monitoring the readings at an interval of 1, 3, 5, 10, 15, 30, 60, 90, 120, 180, 240, and 300 minutes intraoperatively following the subarachnoid blockade. The requirement of postoperative analgesia and regression of sensory and motor levels of the blockade was evaluated every 60 minutes for the next 4 hours in the recovery unit during the observation period. Visual analogue scale (VAS) were taught how to expess the degree of pain on the scale of 0 to 10 and were asked to mark on the scale according to the degree of pain. When VAS score was more than 4, rescue analgesia was given with injection tramadol 25mg intravenously.

 

Management protocol for drug-related complications :

     The hemodynamic parameters were monitored. Hypotension was noted when systolic Blood Pressure recorded less than 90mmHg and was treated with intravenous crystalloids and if needed vasopressors like an injection of Mephentermine 6mg IV as incremental bolus doses. Bradycardia was noted when the heart rate was less than 50 beats per minute and treated with Injection Glycopyrrolate 0.02mg per kilogram IV as bolus if required. Injection of Ondansetron 4mg IV supplemented if there is nausea or vomiting.

 

Statistical analysis :

    The observations and results were compiled and data were statistically analyzed using the SPSS 28.0 software using Chisquare and Kruskal-wallis one way analysis. Baseline characteristics were presented as mean ± S.D. Binomial data were compared using Chi-square test (p value less than 0.05 were considered as statistically significant) and block characteristics using Kruskal-Wallis one way analysis. Two-tailed Mann-Whitney U test for multiple two way testing to see post hoc comparisons within-subject variability for statistical significance.

 
Close